AltheaDx, which offers personalized genetic diagnostic tests to predict adverse drug reactions, postponed its IPO on Wednesday. The San Diego, CA-based company was founded in 2008 and booked $17 million in sales for the twelve months ended September 30, 2014. Citi and Jefferies & Co. were set to be the joint bookrunners on the deal.